Earlier this year, over a dozen new prescription drugs hit the market, treating conditions from diabetes to hyperlipidemia to osteoporosis and rheumatoid arthritis. Those wondering whether to take these drugs or seek alternative treatments should know the benefits and drawbacks of such drugs. Here’s a brief rundown of just a few of the newest drugs to hit the market this past spring:
Tocilizumab – a biological agent for the treatment of rheumatoid arthritis. Your doctor has to administer this drug via I.V. or intravenous delivery. This one comes with a variety of warnings and adverse reactions such as upper respiratory tract infection and hypertension. However, it can be used in combination with other DMARDs (disease-modifying antirheumatic drugs) for those diagnosed with moderate to severe RA.
Dalfampridine – mainly used in the treatment of multiple sclerosis, Dalfampridine, also known as Acorda or Ampyra, is a potassium channel blocker. Designed to facilitate movement and walking ability for patients, it was shown to increase stability and walking speed during clinical trials. Results in trials were 50/50 for showing improvement. Adverse reactions include dizziness, nausea and balance disorder.
Denosumab – this drug binds to proteins in the body responsible for the formation of osteoclasts, those cells charged with bone resorption. The drug reduces loss of bone mass and strength, often prescribed for those diagnosed with osteoporosis. Adverse reactions to this drug include musculoskeletal pain and skin reactions.
Regardless of origin, patients and consumers should learn as much about drugs prescribed by their physicians as possible. PlacidWay, an international medical resource and provider, is dedicated to offering information for patients making decisions regarding their medical care, at home or abroad.
Tags: Acorda, alternative treatments, Ampyra, bioligical agents, bone disease, bone loss, bone mass, cost of drug therapy for rheumatoid arthritis, cost of drugs, Dalfampridine, Denosumab, diabetes, disear-modifying antirheumatic drugs, DMARDs, drug clinical trials, drug therapies, drug therapy, drug therapy abroad, drug therapy costs, drug therapy for multiple sclerosis, drug therapy for osteoporisis abroad, drug treatments for MS, drug treatments for rheumatoid arthritis, drugs for bone loss, drugs for diabetes, drugs for hyperlipidemia, drugs for osteoporosis, hyperlipidemia, international medical resources, medical care, medical care abroad, medical information, medical providers, Medical Tourism, Medical tourists, medical travel, medications, moderate RA, multiple sclerosis, osteoporosis, osteoporosis drug therapy, PlacidWay, PlacidWay.com, potassium channel blocker, prescription drugs, RA, RA drug therapy, rheumatoid arthritis, severe RA drug therapy, Tocilizumab
Warning: Use of undefined constant PWP_NAME - assumed 'PWP_NAME' (this will throw an Error in a future version of PHP) in /home/u255626122/domains/placidblog.com/public_html/wp-content/mu-plugins/mu-plugin.php on line 148